PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Journal of Bone Metabolism10.11005/jbm.2020.27.3.1512020273151-165Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?Joonho Suh, Yun-Sil Leehttp://e-jbm.org/upload/pdf/jbm-2020-27-3-151.pdf, http://e-jbm.org/journal/view.php?doi=10.11005/jbm.2020.27.3.151, http://e-jbm.org/upload/pdf/jbm-2020-27-3-151.pdf
Tourism Management Perspectives10.1016/j.tmp.2015.01.0022015143-16Ecotourism: A panacea or a predicament?Madhumita Das, Bani Chatterjeehttps://api.elsevier.com/content/article/PII:S2211973615000185?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2211973615000185?httpAccept=text/plain
Neuromuscular Disorders10.1016/j.nmd.2007.06.0862007179-10785G.P.3.11 Novel myostatin inhibitors increase muscle mass in wild-type and mdx miceJ. Lachey, A. Pullen, R. Pearsall, J. Seehrahttps://api.elsevier.com/content/article/PII:S0960896607002738?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960896607002738?httpAccept=text/plain
Neuromuscular Disorders10.1016/j.nmd.2012.06.2042012229-10864T.P.39 Building muscle with myostatin inhibitorsP. Bialek, J. Owens, M. St. Andre, D. Marsden, M. Denz, P. Yaworsky, C. Morrishttps://api.elsevier.com/content/article/PII:S0960896612003860?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960896612003860?httpAccept=text/plain
BMC Musculoskeletal Disorders10.1186/s12891-021-04030-02021221Myostatin and markers of bone metabolism in dermatomyositisKatharina Kerschan-Schindl, Wolfgang Gruther, Ursula Föger-Samwald, Christine Bangert, Stefan Kudlacek, Peter Pietschmannhttp://link.springer.com/content/pdf/10.1186/s12891-021-04030-0.pdf, http://link.springer.com/article/10.1186/s12891-021-04030-0/fulltext.html, http://link.springer.com/content/pdf/10.1186/s12891-021-04030-0.pdf
Neuromuscular Disorders10.1016/j.nmd.2004.10.0182005152117-126The function of Myostatin and strategies of Myostatin blockade—new hope for therapies aimed at promoting growth of skeletal muscleKetan Patel, Helge Amthorhttps://api.elsevier.com/content/article/PII:S0960896604003098?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960896604003098?httpAccept=text/plain
Neuromuscular Disorders10.1016/j.nmd.2008.03.0092008185432Myostatin blockade – therapy or body building?Helge Amthorhttps://api.elsevier.com/content/article/PII:S0960896608000692?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960896608000692?httpAccept=text/plain
Reactions Weekly10.1007/s40278-014-8619-42014148718-8Antihyperglycaemics/HMG-CoA reductase inhibitorshttp://link.springer.com/content/pdf/10.1007/s40278-014-8619-4.pdf, http://link.springer.com/article/10.1007/s40278-014-8619-4/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-014-8619-4
Work-related Musculoskeletal Disorders10.5772/intechopen.854792019Introductory Chapter: Work-Related Musculoskeletal DisordersOrhan Korhan, Asad Ahmed Memonhttp://www.intechopen.com/download/pdf/66431
Neuromuscular Disorders10.1016/j.nmd.2007.06.0912007179-10787G.P.3.16 In skeletal muscle of patients with type-II fiber atrophy, myostatin (MSTN) and myostatin precursor protein (MSTN-PP) are both increasedS. Wojcik, A. Nogalska, W.K. Engel, V. Askanashttps://api.elsevier.com/content/article/PII:S0960896607002787?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960896607002787?httpAccept=text/plain